GLUE
Monte Rosa Therapeutics Inc
NASDAQ · Biotechnology
$19.55
+0.65 (+3.44%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 78.01M | 401.98M | 400.93M | 375.33M |
| Net Income | -74,992,375 | -29,192,444 | -34,329,564 | -33,264,511 |
| EPS | — | — | — | — |
| Profit Margin | -96.1% | -7.3% | -8.6% | -8.9% |
| Rev Growth | — | +22.8% | -9.2% | -6.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 539.88M | 596.36M | 525.46M |
| Total Equity | — | 1.24B | 1.24B | 1.15B |
| D/E Ratio | — | 0.43 | 0.48 | 0.46 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -75,297,346 | -51,685,540 | -47,809,490 | -46,631,390 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 | -47,871,864 |